|
FY 2019
|
Q4 2019
|
||||
|
$m
|
% change
|
$m
|
% change
|
||
|
Actual
|
CER
|
Actual
|
CER
|
||
Product Sales
|
23,565
|
12
|
15
|
6,250
|
8
|
9
|
Collaboration Revenue
|
819
|
(21)
|
(20)
|
414
|
(36)
|
(36)
|
Total Revenue
|
24,384
|
10
|
13
|
6,664
|
4
|
5
|
|
|
|
|
|
|
|
Reported5 Operating
Profit
|
2,924
|
(14)
|
(16)
|
577
|
(46)
|
(56)
|
Core6 Operating Profit
|
6,436
|
13
|
13
|
1,545
|
(29)
|
(33)
|
|
|
|
|
|
|
|
Reported EPS7
|
$1.03
|
(40)
|
(44)
|
$0.24
|
(71)
|
(78)
|
Core EPS
|
$3.50
|
1
|
-
|
$0.89
|
(44)
|
(46)
|
|
FY 2019
|
Q4 2019
|
||||
|
$m
|
% change
|
$m
|
% change
|
||
|
Actual
|
CER
|
Actual
|
CER
|
||
Tagrisso
|
3,189
|
71
|
74
|
884
|
49
|
49
|
Imfinzi
|
1,469
|
n/m
|
n/m
|
424
|
62
|
62
|
Lynparza
|
1,198
|
85
|
89
|
351
|
68
|
69
|
Calquence
|
164
|
n/m
|
n/m
|
56
|
n/m
|
n/m
|
|
FY 2019
|
Q4 2019
|
||||
|
$m
|
% change
|
$m
|
% change
|
||
|
Actual
|
CER
|
Actual
|
CER
|
||
Farxiga
|
1,543
|
11
|
14
|
419
|
6
|
7
|
Brilinta
|
1,581
|
20
|
23
|
428
|
14
|
15
|
Bydureon
|
549
|
(6)
|
(5)
|
139
|
1
|
1
|
|
FY 2019
|
Q4 2019
|
||||
|
$m
|
% change
|
$m
|
% change
|
||
|
Actual
|
CER
|
Actual
|
CER
|
||
Symbicort
|
2,495
|
(3)
|
-
|
712
|
12
|
13
|
Pulmicort
|
1,466
|
14
|
18
|
413
|
6
|
7
|
Fasenra
|
704
|
n/m
|
n/m
|
206
|
65
|
65
|
Regulatory
approvals
|
- Imfinzi -
unresectable[10],
Stage III NSCLC[11] (CN)
- Lynparza -
ovarian cancer (1st line[12],
BRCAm[13])
(SOLO-1) (CN)
- Lynparza -
pancreatic cancer (1st line, BRCAm) (US)
- Enhertu -
breast cancer (3rd line, HER2+[14])
(US)
- Calquence -
CLL[15] (US)
- Qtrilmet -
T2D[16] (EU)
- Lokelma -
hyperkalaemia (CN)
- Breztri -
COPD[17] (CN)
|
Regulatory
submission acceptances and/or submissions
|
- Imfinzi -
SCLC[18] (ED[19]):
regulatory submission (JP), acceptance (EU), Priority Review
(US)
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): regulatory submission (JP),
acceptance (EU), Priority Review (US)
- Lynparza -
prostate cancer (2nd line): regulatory submission acceptance (EU),
Priority Review (US)
- Calquence -
CLL: regulatory submission (JP), acceptance (EU)
- selumetinib -
NF1[20]:
regulatory submission acceptance, Priority Review
(US)
- Farxiga -
HF[21] CVOT[22]:
regulatory submission (JP, CN), acceptance (EU), Priority Review
(US)
- Brilinta -
CAD[23]/T2D
CVOT: regulatory submission (JP, CN)
- roxadustat -
anaemia from CKD[24]:
regulatory submission acceptance (US)8
- Symbicort -
mild asthma: regulatory submission (CN)
|
Major
Phase
III data readouts or other significant developments
|
- Imfinzi +/-
treme - NSCLC (1st line) (POSEIDON): met Phase III primary endpoint
(PFS[25])
- Imfinzi,
tremelimumab - HCC[26]:
Orphan Drug Designation (US)
- Enhertu -
gastric cancer (3rd line, HER2+): met Phase II primary and key
secondary (OS[27])
endpoints
- Brilinta -
stroke: met Phase III primary endpoint
- Epanova -
mixed dyslipidaemia: Phase III terminated as unlikely to meet
primary endpoint
- roxadustat
- anaemia from CKD: met Phase III pooled safety
objective
- cotadutide -
NASH[28]:
Fast Track designation (US)
|
Timing
|
News
flow
|
H1 2020
|
- Imfinzi -
SCLC (ED): regulatory decision (US)
- Imfinzi +/-
treme - bladder cancer (1st line) (DANUBE): data readout,
regulatory submission
- Imfinzi +/-
treme - head & neck cancer (1st line): data readout, regulatory
submission
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): regulatory decision
(US)
- Lynparza -
breast cancer (BRCAm): regulatory decision (CN)
- Lynparza -
prostate cancer (2nd line): regulatory decision (US)
- Lynparza +
cediranib - ovarian cancer (2nd line): data readout
- Enhertu -
breast cancer (3rd line, HER2+): regulatory decision
(JP)
- Enhertu -
gastric cancer (3rd line, HER2+): regulatory
submission
- selumetinib
- NF1: regulatory decision (US)
- selumetinib
- NF1: regulatory submission (EU)
- Forxiga -
T2D CVOT: regulatory decision (CN)
- Farxiga -
HF CVOT: regulatory decision (US)
- Brilinta -
stroke (THALES): regulatory submission
- Lokelma -
hyperkalaemia: regulatory decision (JP)
- Symbicort -
mild asthma: regulatory submission (EU)
- Bevespi -
COPD: regulatory decision (CN)
|
H2 2020
|
- Imfinzi -
unresectable, Stage III NSCLC (PACIFIC-2): data
readout
- Imfinzi -
SCLC (ED): regulatory decision (EU, JP)
- Imfinzi -
SCLC (ED): regulatory submission (CN)
- Imfinzi +/-
treme - HCC (1st line): data readout
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): regulatory decision
(EU)
- Lynparza -
ovarian cancer (3rd line, BRCAm): regulatory submission
(US)
- Lynparza -
pancreatic cancer (1st line, BRCAm): regulatory decision
(EU)
- Lynparza -
prostate cancer (2nd line): regulatory decision (EU)
- Enhertu -
breast cancer (3rd line, HER2+): regulatory submission
(EU)
- Calquence -
CLL: regulatory decision (EU)
- Forxiga -
HF CVOT: regulatory decision (EU, JP, CN)
- Brilinta/Brilique -
CAD/T2D CVOT: regulatory decision (US, EU)
- roxadustat
- anaemia from CKD: regulatory decision (US)
- Symbicort -
mild asthma: regulatory decision (CN)
- Fasenra -
nasal polyposis: data readout
- PT010
- COPD: regulatory decision (US, EU)
- PT027
- asthma: data readout
- tezepelumab
- severe asthma: data readout
- anifrolumab
- lupus (SLE[29]):
regulatory submission
|
2021
|
- Imfinzi -
adjuvant NSCLC: data readout, regulatory submission
- Imfinzi -
unresectable, Stage III NSCLC (PACIFIC-2): regulatory
submission
- Imfinzi +/-
treme - NSCLC (1st line) (POSEIDON): data readout (OS), regulatory
submission
- Imfinzi +/-
treme - SCLC (LD[30]): data
readout
- Imfinzi +/-
treme - HCC (1st line): regulatory submission
- Imfinzi -
HCC (locoregional): data readout, regulatory
submission
- Lynparza -
adjuvant breast cancer: data readout, regulatory
submission
- Lynparza -
prostate cancer (1st line, castration-resistant): data readout,
regulatory submission
- Lynparza +
cediranib - ovarian cancer (2nd line): regulatory
submission
- Enhertu -
breast cancer (3rd line, HER2+) (Phase III): data readout,
regulatory submission
- Enhertu -
breast cancer (2nd line, HER2+): data readout
- Enhertu -
breast cancer (HER2-low): data readout
- Calquence -
CLL: regulatory decision (JP)
- Farxiga -
chronic kidney disease: data readout, regulatory
submission
- roxadustat -
anaemia from myelodysplastic syndrome[31]:
data readout
- Fasenra -
nasal polyposis: regulatory submission
- PT027
- asthma: regulatory submission
- tezepelumab
- severe asthma: regulatory submission
|
|
FY 2019
|
Q4 2019
|
||||
|
$m
|
% change
|
$m
|
% change
|
||
|
Actual
|
CER
|
Actual
|
CER
|
||
Product Sales
|
23,565
|
12
|
15
|
6,250
|
8
|
9
|
Collaboration Revenue
|
819
|
(21)
|
(20)
|
414
|
(36)
|
(36)
|
|
|
|
|
|
|
|
Total Revenue
|
24,384
|
10
|
13
|
6,664
|
4
|
5
|
|
FY 2019
|
Q4 2019
|
||||||
|
$m
|
|
% change
|
$m
|
|
% change
|
||
|
% of total
|
Actual
|
CER
|
% of total
|
Actual
|
CER
|
||
Oncology
|
8,667
|
37
|
44
|
47
|
2,274
|
36
|
29
|
29
|
BioPharmaceuticals
|
9,767
|
41
|
10
|
13
|
2,705
|
43
|
10
|
11
|
New CVRM
|
4,376
|
19
|
9
|
12
|
1,168
|
19
|
6
|
7
|
Respiratory
|
5,391
|
23
|
10
|
13
|
1,537
|
25
|
13
|
14
|
Other medicines
|
5,131
|
22
|
(16)
|
(13)
|
1,271
|
20
|
(17)
|
(16)
|
|
|
|
|
|
|
|
|
|
Total
|
23,565
|
100
|
12
|
15
|
6,250
|
100
|
8
|
9
|
Medicine
|
Therapy Area
|
FY 2019
|
Q4 2019
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
||||
Actual
|
CER
|
Actual
|
CER
|
|||||
Tagrisso
|
Oncology
|
3,189
|
14
|
71
|
74
|
884
|
49
|
49
|
Symbicort
|
Respiratory
|
2,495
|
11
|
(3)
|
-
|
712
|
12
|
13
|
Brilinta
|
CVRM
|
1,581
|
7
|
20
|
23
|
428
|
14
|
15
|
Farxiga
|
CVRM
|
1,543
|
7
|
11
|
14
|
419
|
6
|
7
|
Nexium
|
Other medicines
|
1,483
|
6
|
(13)
|
(11)
|
353
|
(10)
|
(10)
|
Imfinzi
|
Oncology
|
1,469
|
6
|
n/m
|
n/m
|
424
|
62
|
62
|
Pulmicort
|
Respiratory
|
1,466
|
6
|
14
|
18
|
413
|
6
|
7
|
Crestor
|
CVRM
|
1,278
|
5
|
(11)
|
(8)
|
296
|
(16)
|
(15)
|
Lynparza
|
Oncology
|
1,198
|
5
|
85
|
89
|
351
|
68
|
69
|
Faslodex
|
Oncology
|
892
|
4
|
(13)
|
(11)
|
166
|
(39)
|
(38)
|
|
|
|
|
|
|
|
|
|
Total
|
|
16,594
|
70
|
20
|
23
|
4,446
|
15
|
16
|
|
FY 2019
|
Q4 2019
|
|||||
|
$m
|
% of total
|
% change
|
$m
|
% change
|
||
|
Actual
|
CER
|
Actual
|
CER
|
|||
Initial Collaboration Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
Ongoing Collaboration Revenue
|
819
|
100
|
(21)
|
(20)
|
414
|
(36)
|
(36)
|
Royalties
|
62
|
8
|
29
|
34
|
18
|
59
|
63
|
Milestones/other: Lynparza
|
610
|
74
|
(23)
|
(20)
|
350
|
(44)
|
(43)
|
Milestones/other: nirsevimab[32]
|
34
|
4
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
Other Milestones/other
|
113
|
14
|
(19)
|
(18)
|
46
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
Total
|
819
|
100
|
(21)
|
(20)
|
414
|
(36)
|
(36)
|
Therapy area
|
Medicine
|
FY 2019
|
Q4 2019
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
||||
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
Tagrisso
|
3,189
|
14
|
71
|
74
|
884
|
49
|
49
|
Imfinzi
|
1,469
|
6
|
n/m
|
n/m
|
424
|
62
|
62
|
|
Lynparza
|
1,198
|
5
|
85
|
89
|
351
|
68
|
69
|
|
Calquence
|
164
|
1
|
n/m
|
n/m
|
56
|
n/m
|
n/m
|
|
Faslodex[33]
|
892
|
4
|
(13)
|
(11)
|
166
|
(39)
|
(38)
|
|
Zoladex33
|
813
|
3
|
8
|
13
|
196
|
8
|
9
|
|
Iressa33
|
423
|
2
|
(18)
|
(15)
|
80
|
(29)
|
(28)
|
|
Arimidex33
|
225
|
1
|
6
|
11
|
51
|
10
|
11
|
|
Casodex33
|
200
|
1
|
-
|
3
|
43
|
(6)
|
(5)
|
|
Others
|
94
|
-
|
(18)
|
(17)
|
26
|
15
|
12
|
|
Total Oncology
|
8,667
|
37
|
44
|
47
|
2,274
|
29
|
29
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
1,543
|
7
|
11
|
14
|
419
|
6
|
7
|
Brilinta
|
1,581
|
7
|
20
|
23
|
428
|
14
|
15
|
|
Bydureon
|
549
|
2
|
(6)
|
(5)
|
139
|
1
|
1
|
|
Onglyza
|
527
|
2
|
(3)
|
-
|
131
|
(11)
|
(10)
|
|
Byetta
|
110
|
-
|
(13)
|
(11)
|
27
|
(16)
|
(15)
|
|
Other diabetes
|
52
|
-
|
33
|
35
|
16
|
35
|
36
|
|
Lokelma
|
14
|
-
|
n/m
|
n/m
|
8
|
n/m
|
n/m
|
|
Crestor33
|
1,278
|
5
|
(11)
|
(8)
|
296
|
(16)
|
(15)
|
|
Seloken/Toprol-XL33
|
760
|
3
|
7
|
12
|
190
|
18
|
20
|
|
Atacand33
|
221
|
1
|
(15)
|
(11)
|
60
|
3
|
5
|
|
Others
|
271
|
1
|
(9)
|
(6)
|
72
|
1
|
4
|
|
BioPharmaceuticals: total CVRM
|
6,906
|
29
|
3
|
6
|
1,785
|
2
|
4
|
|
BioPharmaceuticals: Respiratory
|
Symbicort
|
2,495
|
11
|
(3)
|
-
|
712
|
12
|
13
|
Pulmicort
|
1,466
|
6
|
14
|
18
|
413
|
6
|
7
|
|
Fasenra
|
704
|
3
|
n/m
|
n/m
|
206
|
65
|
65
|
|
Daliresp/Daxas
|
215
|
1
|
14
|
15
|
58
|
8
|
8
|
|
Duaklir
|
77
|
-
|
(19)
|
(15)
|
22
|
(2)
|
-
|
|
Bevespi
|
42
|
-
|
26
|
26
|
12
|
12
|
12
|
|
Breztri
|
2
|
-
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
|
Others
|
390
|
2
|
(13)
|
(9)
|
114
|
(9)
|
(7)
|
|
BioPharmaceuticals: total Respiratory
|
5,391
|
23
|
10
|
13
|
1,537
|
13
|
14
|
|
Other medicines
|
Nexium
|
1,483
|
6
|
(13)
|
(11)
|
353
|
(10)
|
(10)
|
Synagis
|
358
|
2
|
(46)
|
(46)
|
63
|
(75)
|
(75)
|
|
Losec/Prilosec
|
263
|
1
|
(3)
|
1
|
46
|
(24)
|
(23)
|
|
Seroquel XR/IR
|
191
|
1
|
(47)
|
(46)
|
40
|
(27)
|
(27)
|
|
Others
|
306
|
1
|
(23)
|
(20)
|
151
|
12
|
14
|
|
Total other medicines
|
2,601
|
11
|
(24)
|
(21)
|
653
|
(27)
|
(27)
|
|
|
Total Product Sales
|
23,565
|
100
|
12
|
15
|
6,250
|
8
|
9
|
|
FY 2019
|
Q4 2019
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Emerging Markets
|
8,165
|
35
|
18
|
24
|
2,091
|
18
|
20
|
China
|
4,880
|
21
|
29
|
35
|
1,189
|
25
|
28
|
Ex-China
|
3,285
|
14
|
6
|
12
|
902
|
10
|
11
|
|
|
|
|
|
|
|
|
US
|
7,747
|
33
|
13
|
13
|
2,059
|
1
|
1
|
|
|
|
|
|
|
|
|
Europe
|
4,350
|
18
|
(2)
|
2
|
1,182
|
1
|
4
|
|
|
|
|
|
|
|
|
Established RoW
|
3,303
|
14
|
17
|
18
|
918
|
16
|
13
|
Japan
|
2,548
|
11
|
27
|
26
|
719
|
22
|
17
|
Canada
|
470
|
2
|
(4)
|
(1)
|
126
|
(4)
|
(3)
|
Other Established RoW
|
285
|
1
|
(13)
|
(4)
|
73
|
5
|
10
|
|
|
|
|
|
|
|
|
Total
|
23,565
|
100
|
12
|
15
|
6,250
|
8
|
9
|
|
FY 2019
|
Q4 2019
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Oncology
|
2,211
|
27
|
45
|
52
|
546
|
54
|
57
|
BioPharmaceuticals
|
3,120
|
38
|
25
|
31
|
865
|
18
|
20
|
New CVRM
|
1,133
|
14
|
33
|
41
|
297
|
25
|
27
|
Respiratory
|
1,987
|
24
|
21
|
27
|
568
|
14
|
16
|
Other medicines
|
2,834
|
35
|
(1)
|
4
|
680
|
1
|
2
|
|
|
|
|
|
|
|
|
Total
|
8,165
|
100
|
18
|
24
|
2,091
|
18
|
20
|
Product Sales
|
FY 2019
$m
|
% change
|
|
Actual
|
CER
|
||
Tagrisso
|
762
|
n/m
|
n/m
|
Lynparza
|
133
|
n/m
|
n/m
|
Farxiga
|
471
|
40
|
48
|
Brilinta
|
462
|
42
|
49
|
Product Sales
|
FY 2019
$m
|
% change
|
|
Actual
|
CER
|
||
Zoladex
|
492
|
20
|
28
|
Pulmicort
|
1,190
|
20
|
24
|
Symbicort
|
547
|
11
|
17
|
Product Sales
|
FY 2019
|
|
% change
|
||
Actual
|
CER
|
|
Russia
|
35
|
40
|
Brazil
|
(2)
|
7
|
Ex-Brazil
Latin America
|
3
|
16
|
Ex-China
Asia Pacific
|
8
|
10
|
Middle
East and Africa
|
3
|
8
|
|
FY 2019
|
FY 2018
|
% change
|
Q4 2019
|
Q4 2018
|
% change
|
||
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
Product Sales
|
23,565
|
21,049
|
12
|
15
|
6,250
|
5,768
|
8
|
9
|
Collaboration Revenue
|
819
|
1,041
|
(21)
|
(20)
|
414
|
649
|
(36)
|
(36)
|
Total Revenue
|
24,384
|
22,090
|
10
|
13
|
6,664
|
6,417
|
4
|
5
|
|
|
|
|
|
|
|
|
|
Cost of Sales
|
(4,921)
|
(4,936)
|
-
|
5
|
(1,378)
|
(1,637)
|
(16)
|
(10)
|
|
|
|
|
|
|
|
|
|
Gross Profit
|
19,463
|
17,154
|
13
|
16
|
5,286
|
4,780
|
11
|
10
|
Gross Profit
Margin[37]
|
79.1%
|
76.6%
|
3
|
2
|
78.0%
|
71.6%
|
6
|
5
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(339)
|
(331)
|
2
|
7
|
(92)
|
(93)
|
(2)
|
-
|
% Total Revenue
|
1.4%
|
1.5%
|
-
|
-
|
1.4%
|
1.5%
|
-
|
-
|
R&D Expense
|
(6,059)
|
(5,932)
|
2
|
5
|
(2,091)
|
(2,012)
|
4
|
5
|
% Total Revenue
|
24.8%
|
26.9%
|
2
|
2
|
31.4%
|
31.4%
|
-
|
-
|
SG&A Expense
|
(11,682)
|
(10,031)
|
16
|
20
|
(3,026)
|
(2,600)
|
16
|
18
|
% Total Revenue
|
47.9%
|
45.4%
|
(2)
|
(3)
|
45.4%
|
40.5%
|
(5)
|
(5)
|
|
|
|
|
|
|
|
|
|
Total Operating Expenses
|
(18,080)
|
(16,294)
|
11
|
14
|
(5,209)
|
(4,705)
|
11
|
12
|
% Total Revenue
|
74.1%
|
73.8%
|
-
|
-
|
78.2%
|
73.3%
|
(5)
|
(5)
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
1,541
|
2,527
|
(39)
|
(38)
|
500
|
1,002
|
(50)
|
(50)
|
% Total Revenue
|
6.3%
|
11.4%
|
(5)
|
(5)
|
7.5%
|
15.6%
|
(8)
|
(8)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
2,924
|
3,387
|
(14)
|
(16)
|
577
|
1,077
|
(46)
|
(56)
|
Operating Profit Margin
|
12.0%
|
15.3%
|
(3)
|
(4)
|
8.7%
|
16.8%
|
(8)
|
(10)
|
Net Finance Expense
|
(1,260)
|
(1,281)
|
(2)
|
4
|
(312)
|
(311)
|
-
|
(1)
|
Joint Ventures and Associates
|
(116)
|
(113)
|
3
|
5
|
(25)
|
(36)
|
(30)
|
(30)
|
Profit Before Tax
|
1,548
|
1,993
|
(22)
|
(29)
|
240
|
730
|
(67)
|
(79)
|
Taxation
|
(321)
|
57
|
n/m
|
n/m
|
37
|
279
|
(87)
|
(81)
|
Tax Rate
|
21%
|
-3%
|
|
|
-15%
|
-38%
|
|
|
Profit After Tax
|
1,227
|
2,050
|
(40)
|
(45)
|
277
|
1,009
|
(72)
|
(80)
|
|
|
|
|
|
|
|
|
|
EPS
|
1.03
|
1.70
|
(40)
|
(44)
|
0.24
|
0.82
|
(71)
|
(78)
|
|
FY 2019
|
FY 2018
|
% change
|
Q4 2019
|
Q4 2018
|
% change
|
||
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
Reported Profit Before Tax
|
1,548
|
1,993
|
(22)
|
(29)
|
240
|
730
|
(67)
|
(79)
|
Net Finance Expense
|
1,260
|
1,281
|
(2)
|
4
|
312
|
311
|
-
|
(1)
|
Joint Ventures and Associates
|
116
|
113
|
3
|
5
|
25
|
36
|
(30)
|
(30)
|
Depreciation, Amortisation and Impairment
|
3,762
|
3,753
|
-
|
3
|
1,643
|
1,662
|
(1)
|
-
|
|
|
|
|
|
|
|
|
|
EBITDA
|
6,686
|
7,140
|
(6)
|
(6)
|
2,220
|
2,739
|
(19)
|
(22)
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other[39]
|
Core[40]
|
Core % change
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
Gross Profit
|
19,463
|
73
|
87
|
-
|
-
|
19,623
|
10
|
13
|
Gross Profit Margin
|
79.1%
|
|
|
|
|
79.8%
|
-
|
-
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(339)
|
-
|
-
|
-
|
-
|
(339)
|
2
|
7
|
R&D Expense
|
(6,059)
|
101
|
638
|
-
|
-
|
(5,320)
|
1
|
4
|
SG&A Expense
|
(11,682)
|
173
|
1,771
|
(126)
|
775
|
(9,089)
|
5
|
8
|
Total Operating Expenses
|
(18,080)
|
274
|
2,409
|
(126)
|
775
|
(14,748)
|
4
|
7
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
1,541
|
-
|
1
|
-
|
19
|
1,561
|
(27)
|
(26)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
2,924
|
347
|
2,497
|
(126)
|
794
|
6,436
|
13
|
13
|
Operating Profit Margin
|
12.0%
|
|
|
|
|
26.4%
|
+1
|
-
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(1,260)
|
-
|
-
|
287
|
208
|
(765)
|
4
|
10
|
Taxation
|
(321)
|
(66)
|
(519)
|
(54)
|
(149)
|
(1,109)
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
EPS
|
$1.03
|
$0.22
|
$1.52
|
$0.08
|
$0.65
|
$3.50
|
1
|
-
|
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other41
|
Core42
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
5,286
|
(49)
|
18
|
-
|
-
|
5,255
|
1
|
1
|
Gross Profit Margin
|
78.0%
|
|
|
|
|
77.5%
|
-1
|
-2
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(92)
|
-
|
-
|
-
|
-
|
(92)
|
(2)
|
-
|
R&D Expense
|
(2,091)
|
19
|
578
|
-
|
-
|
(1,494)
|
2
|
4
|
SG&A Expense
|
(3,026)
|
26
|
762
|
(420)
|
33
|
(2,625)
|
8
|
9
|
Total Operating Expenses
|
(5,209)
|
45
|
1,340
|
(420)
|
33
|
(4,211)
|
5
|
7
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
500
|
-
|
(2)
|
-
|
3
|
501
|
(50)
|
(50)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
577
|
(4)
|
1,356
|
(420)
|
36
|
1,545
|
(29)
|
(33)
|
Operating Profit Margin
|
8.7%
|
|
|
|
|
23.2%
|
-11
|
-12
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(312)
|
-
|
-
|
71
|
55
|
(186)
|
6
|
-
|
Taxation
|
37
|
8
|
(279)
|
52
|
(13)
|
(195)
|
n/m
|
n/m
|
EPS
|
$0.24
|
-
|
$0.83
|
($0.23)
|
$0.05
|
$0.89
|
(44)
|
(46)
|
|
FY 2019
|
FY 2018
|
Change
|
|
$m
|
$m
|
$m
|
Reported Operating Profit
|
2,924
|
3,387
|
(463)
|
Depreciation, Amortisation and Impairment
|
3,762
|
3,753
|
9
|
|
|
|
|
Increase in Working Capital and Short-Term Provisions
|
(346)
|
(639)
|
293
|
Gains on Disposal of Intangible Assets
|
(1,243)
|
(1,885)
|
642
|
Non-Cash and Other Movements
|
(236)
|
(785)
|
549
|
Interest Paid
|
(774)
|
(676)
|
(98)
|
Taxation Paid
|
(1,118)
|
(537)
|
(581)
|
|
|
|
|
Net Cash Inflow from Operating Activities
|
2,969
|
2,618
|
351
|
|
|
|
|
Net Cash Inflow before Financing Activities
|
2,312
|
3,581
|
(1,269)
|
Net Cash Outflow from Financing Activities
|
(1,765)
|
(2,044)
|
279
|
|
At
31 Dec 2019
|
At
31 Dec 2018
|
|
$m
|
$m
|
Cash and Cash Equivalents
|
5,369
|
4,831
|
Other Investments
|
911
|
895
|
|
|
|
Cash and Investments
|
6,280
|
5,726
|
|
|
|
Overdrafts and Short-Term Borrowings
|
(225)
|
(755)
|
Lease Liabilities[42]
|
(675)
|
-
|
Current Instalments of Loans
|
(1,597)
|
(999)
|
Loans Due After One Year
|
(15,730)
|
(17,359)
|
|
|
|
Interest-Bearing Loans and Borrowings (Gross Debt)
|
(18,227)
|
(19,113)
|
|
|
|
Net Derivatives
|
43
|
384
|
Net Debt
|
(11,904)
|
(13,003)
|
|
Average Exchange
Rates versus USD
|
|
Annual Impact of 5% Strengthening in Exchange Rate versus USD
($m)[43]
|
|||
Currency
|
Primary Relevance
|
FY 2019[44]
|
YTD 2020[45]
|
% change
|
Product Sales
|
Core Operating Profit
|
CNY
|
Product
Sales
|
6.92
|
6.93
|
-
|
288
|
190
|
EUR
|
Product
Sales
|
0.89
|
0.90
|
(1)
|
171
|
68
|
JPY
|
Product
Sales
|
108.98
|
109.38
|
-
|
139
|
98
|
Other[46]
|
|
|
|
|
231
|
123
|
|
|
|
|
|
|
|
GBP
|
Operating
Expense
|
0.78
|
0.77
|
2
|
27
|
(93)
|
SEK
|
Operating
Expense
|
9.46
|
9.47
|
-
|
5
|
(51)
|
New
molecular
entities
and major lifecycle events for medicines in Phase III trials or
under regulatory review
|
17
|
Oncology
- Tagrisso -
NSCLC
- Imfinzi -
multiple cancers
- Lynparza -
multiple cancers
- Enhertu -
breast and other cancers
- capivasertib
- breast cancer
- Calquence -
blood cancers
- tremelimumab
- multiple cancers
- selumetinib -
NF1[50]
- savolitinib
- NSCLC53
CV,
Renal & Metabolism
- roxadustat
- anaemia from CKD
Respiratory
(and immunology)
- Fasenra
- multiple indications
- Breztri -
COPD
- PT027
- asthma
- tezepelumab
- severe asthma
- nirsevimab
- lower respiratory tract infection
- anifrolumab
- lupus
-
brazikumab[51] -
inflammatory bowel disease
|
Total
projects
in
clinical pipeline
|
144
|
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
ADAURA
|
Adjuvant
EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD[52]
Q4
2015
LPCD[53]
Q1
2019
First
data anticipated
2021+[54]
|
Recruitment
completed
|
Phase
III
LAURA
|
Locally
advanced, unresectable EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
FLAURA2
|
1st-line
EGFRm NSCLC
|
Tagrisso or Tagrisso + platinum-based
chemotherapy doublet
|
FPCD
Q4
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
AEGEAN
|
Neo-adjuvant
(before surgery) NSCLC
|
SoC
chemotherapy +/- Imfinzi,
followed
by
surgery,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Phase
III
ADJUVANT BR.31[55]
|
Stage
Ib-IIIa NSCLC
|
Placebo
or
Imfinzi
|
FPCD
Q1
2015
LPCD
Q4
2019
First
data anticipated
2021
|
Recruitment
completed
|
Phase
III
PACIFIC-2
|
Stage
III unresected locally advanced NSCLC
(concurrent
CRT)
|
Placebo
or
Imfinzi
|
FPCD
Q2
2018
LPCD
Q3
2019
First
data anticipated
H2
2020
|
Recruitment
completed
|
Phase
III
ADRIATIC
|
Limited-disease
stage SCLC
|
Concurrent
CRT,
followed
by
placebo
or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment
ongoing
|
Phase
III
POSEIDON
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q2
2017
LPCD
Q4
2018
|
PFS
primary endpoint met
|
Phase
III
CASPIAN
|
Extensive-disease
stage SCLC
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q1
2017
LPCD
Q2
2018
|
OS
primary endpoint met for Imfinzi monotherapy
arm
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
POTOMAC
|
Non-muscle
invasive bladder cancer
|
SoC BCG[56] or
SoC BCG + Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
NIAGARA
|
Muscle-invasive
bladder cancer
|
Neo-adjuvant
cisplatin and gemcitabine SoC chemotherapy or SoC
+ Imfinzi, followed by
adjuvant placebo or Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
EMERALD-1
|
Locoregional
HCC
|
TACE[57] followed
by placebo or TACE + Imfinzi, followed by Imfinzi +
bevacizumab
or
TACE
+ Imfinzi
followed
by Imfinzi
|
FPCD
Q1
2019
First
data
anticipated
2021
|
Recruitment
ongoing
|
Phase
III
EMERALD-2
|
Locoregional
HCC at high risk of recurrence after surgery or radiofrequency
ablation
|
Adjuvant Imfinzi or Imfinzi +
bevacizumab
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
CALLA
|
Locally
advanced cervical cancer
|
CRT or
CRT + Imfinzi,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
DANUBE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible/ineligible bladder
cancer
|
SoC
chemotherapy or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
H1
2020
|
Recruitment
completed
|
Phase
III
NILE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible bladder
cancer
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
KESTREL
|
Stage
IV, 1st-line head and neck squamous cell carcinoma
|
SoC
or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
H1
2020
|
Recruitment
completed
|
Phase
III
HIMALAYA
|
Stage
IV, 1st-line unresectable HCC
|
Sorafenib
or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2017
LPCD
Q4
2019
First
data
anticipated
H2
2020
|
Recruitment
Completed
Orphan
Drug Designation (US)
|
Phase
III
TOPAZ-1
|
Stage
IV, 1st-line biliary-tract cancer
|
Gemcitabine
and cisplatin SoC chemotherapy or SoC + Imfinzi
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
OlympiA
|
Adjuvant
BRCAm breast cancer
|
SoC
placebo or Lynparza
|
FPCD
Q2
2014
LPCD
Q2
2019
First
data anticipated
2021
|
Recruitment
completed
|
Phase
III
PROfound
|
Metastatic castration-resistant 2nd-line+ HRRm[58] prostate
cancer
|
SoC
(abiraterone or enzalutamide) or Lynparza
|
FPCD
Q2
2017
LPCD
Q4
2018
|
Primary
endpoint met
Priority
Review (US)
|
Phase
III
PAOLA-1[59]
|
Advanced
1st-line
ovarian
cancer
|
Bevacizumab
maintenance or
bevacizumab
+
Lynparza maintenance
|
FPCD
Q2
2015
LPCD
Q2
2018
|
Primary
endpoint met
Priority
Review (US)
|
Phase
III
GY004[60]
|
Recurrent
platinum-sensitive ovarian cancer
|
SoC
chemotherapy or Lynparza or cediranib
+ Lynparza
|
FPCD
Q1
2016
First
data
anticipated
H1
2020
|
Recruitment
ongoing
|
Phase
II/III
GY00563
|
Recurrent
platinum-resistant/refractory ovarian cancer
|
SoC
chemotherapy or cediranib or cediranib + Lynparza
|
FPCD
Q2
2016
(Phase
II)
FPCD
Q1
2019
(Phase
III)
First
data
anticipated
2021+
|
Recruitment
ongoing
(Phase
III component)
|
Phase
III
DuO-O
|
Advanced
1st-line
ovarian
cancer
|
Chemotherapy
+
bevacizumab
or
chemotherapy
+
bevacizumab
+
Imfinzi +/-
Lynparza maintenance
|
FPCD
Q1 2019
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
PROpel
|
Stage
IV, advanced, castration-resistant prostate cancer
|
Abiraterone
or
abiraterone
+
Lynparza
|
FPCD
Q4
2018
First
data
anticipated
2021
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
II
DESTINY-Breast01
|
Stage IV, HER2+ (IHC[61] 3+
and IHC 2+/ISH[62]+)
breast cancer post trastuzumab emtansine
|
Enhertu (single arm)
|
FPCD
Q4
2017
LPCD
Q4
2018
|
Primary
objective met
Breakthrough
Therapy Designation (US)
Accelerated
approval (US)
|
Phase
III
DESTINY-Breast02
|
Stage
IV, HER2+ (IHC 3+ and IHC 2+/ISH+) breast cancer post trastuzumab
emtansine
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast03
|
Stage
IV, HER2+ (IHC 3+ and IHC 2+/ISH+) breast cancer
|
Trastuzumab
emtansine or Enhertu
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast04
|
Stage
IV, HER2-low (IHC 1+/2+) breast cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
2021
|
Recruitment ongoing
|
Phase
II
DESTINY-Gastric01
|
Stage
IV, HER2+ (IHC 3+ and IHC 2+/ISH+) gastric cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2017
LPCD
Q2
2019
|
Primary
endpoint met
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Farxiga
|
|
||||
Phase
III
DAPA-HF
|
c.4,500
patients with HF and reduced ejection fraction, with and without
T2D
|
Arm 1: Farxiga 10mg or 5 mg QD[63] +
SoC
Arm 2:
placebo + SoC
|
Time to
first occurrence of CV death or hHF or an urgent HF
visit
|
FPCD
Q1
2017
LPCD
Q4
2018
|
Primary
endpoint met
Fast
Track designation (US)
|
Phase
III
DELIVER
|
c.4,700
patients with HF and preserved ejection fraction, with and without
T2D
|
Arm
1: Farxiga 10mg
QD
Arm 2:
placebo
|
Time to
first occurrence of CV death or worsening HF
|
FPCD
Q4
2018
First
data anticipated 2021+
|
Recruitment
ongoing
Fast
Track designation (US)
|
Phase
III
DAPA-CKD
|
c.4,000
patients with CKD, with and without T2D
|
Arm
1: Farxiga 10mg
or 5mg QD
Arm 2:
placebo
|
Time to first occurrence of ≥ 50% sustained decline in eGFR
or reaching ESRD[64] or
CV death or renal death
|
FPCD
Q1
2017
First
data anticipated 2021
|
Fast
Track designation (US)
|
Brilinta
|
|
||||
Phase
III THEMIS
|
c.19,000 patients with T2D and CAD without a history of
MI[65] or
stroke
|
Arm 1: Brilinta 60mg BID[66]
Arm 2:
placebo BID on a background of acetylsalicylic acid if not
contra-indicated or not tolerated
|
Composite
of CV death, non-fatal MI and non-fatal stroke
|
FPCD
Q1
2014
LPCD
Q2
2016
|
Primary
endpoint met
|
Phase
III
THALES
|
c.11,000
patients with acute ischaemic stroke or transient ischaemic
attack
|
Arm
1: Brilinta 90mg
BID
Arm 2:
placebo BID on a background of acetylsalicylic acid if not
contra-indicated or not tolerated
|
Prevention
of the composite of subsequent stroke and death at 30
days
|
FPCD
Q1
2018
LPCD
Q4 2019
|
Primary
endpoint met
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Phase
III MELTEMI
|
Asthmatic
adults (aged
18-75
years) on ICS plus LABA2 agonist
|
Fasenra 30mg Q4W SC
Fasenra 30mg Q8W SC
|
Safety
and tolerability
|
FPCD
Q2
2016
LPCD
Q1
2017
Data
anticipated
H2
2020
|
Recruitment
completed
|
Phase
IIIb PONENTE
|
Asthmatics (aged 18 years or older) receiving high-dose ICS plus
LABA and chronic OCS[70] with
or without additional asthma controller(s)
|
Fasenra 30mg Q8W SC
38-week
trial
|
Reduction
of OCS dose
|
FPCD
Q3
2018
LPCD
Q3
2019
Data
anticipated
H2
2020
|
Recruitment
completed
|
Phase
III OSTRO
|
Patients
(aged 18-75 years) with severe bilateral nasal polyposis;
symptomatic, despite SoC
|
Placebo
or Fasenra 30mg
Q8W SC
|
Nasal-polyposis
burden and reported nasal blockage
|
FPCD
Q1
2018
LPCD
Q2
2019
Data
anticipated
H2
2020
|
Recruitment
completed
|
Phase
III
MIRACLE
|
Severe
eosinophilic asthma (aged 12-75 years) despite background
controller medication, medium dose and high dose ICS plus LABA
± chronic oral corticosteroids (CN)
|
Placebo
or Fasenra 30mg
Q8W SC
|
Annual
asthma-exacerbation rate
|
FPCD
Q4
2017
Data
anticipated 2021+
|
Recruitment
ongoing
|
Phase
III RESOLUTE
|
Patients
with moderate to very severe COPD with a history of frequent COPD
exacerbations and elevated peripheral blood
eosinophils
|
Placebo
or Fasenra 100mg
Q8W SC
|
Annualised
rate of moderate or severe COPD exacerbations
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
|
Phase
III
MANDARA
|
Eosinophilic granulomatosis with polyangiitis
|
Fasenra 30mg or
mepolizumab
3x100mg Q4W
|
Proportion of patients who achieve remission, defined as a
score[71] =0
and an OCS dose ≤4 mg/day at weeks 36 and
48
|
FPCD
Q4
2019
Data
anticipated
2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
NATRON
|
HES[72]
|
Placebo
or Fasenra 30mg
Q4W SC
|
Time to
HES worsening flare or any cytotoxic and/or immuno-suppressive
therapy increase or hospitalisation
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
MESSINA
|
Eosinophilic
oesophagitis
|
Placebo
or Fasenra 30mg
Q4W SC
|
Proportion
of patients with a histologic response
Changes from baseline in dysphagia PRO[73]
|
Data
anticipated 2021+
|
Initiating
Orphan
Drug Designation (US)
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Phase III
TULIP 1
|
Moderate to severely-active SLE patients on background
SoC
|
Placebo or anifrolumab 150mg or 300mg i.v.
Q4W
|
Response in SLE
responder index at week 52
|
FPCD
Q4 2015
LPCD
Q4 2017
|
Primary endpoint not met
Fast Track designation (US)
|
Phase III
TULIP 2
|
Moderate to severely-active SLE patients on background
SoC
|
Placebo or anifrolumab 300mg i.v.
Q4W
|
Response in BICLA at week 52
|
FPCD
Q4 2015
LPCD
Q4 2017
|
Primary endpoint met
Fast Track designation (US)
|
Phase III
TULIP LTE[76]
|
Moderate to severely active SLE patients on background SoC who have
completed a Phase III anifrolumab trial
|
Placebo or anifrolumab 300mg i.v.
Q4W
|
Long-term safety over 152 weeks
|
FPCD
Q2 2016
LPCD
Q4 2018
Data anticipated
2021+
|
Recruitment completed
Fast Track designation (US)
|
|
2019
|
2018
|
For the year ended 31 December
|
$m
|
$m
|
Product Sales
|
23,565
|
21,049
|
Collaboration Revenue
|
819
|
1,041
|
|
|
|
Total Revenue
|
24,384
|
22,090
|
Cost of sales
|
(4,921)
|
(4,936)
|
|
|
|
Gross Profit
|
19,463
|
17,154
|
Distribution costs
|
(339)
|
(331)
|
Research and development expense
|
(6,059)
|
(5,932)
|
Selling, general and administrative costs
|
(11,682)
|
(10,031)
|
Other operating income and expense
|
1,541
|
2,527
|
|
|
|
Operating Profit
|
2,924
|
3,387
|
Finance income
|
172
|
138
|
Finance expense
|
(1,432)
|
(1,419)
|
Share of after-tax losses in associates and joint
ventures
|
(116)
|
(113)
|
|
|
|
Profit Before Tax
|
1,548
|
1,993
|
Taxation
|
(321)
|
57
|
|
|
|
Profit for the period
|
1,227
|
2,050
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
(364)
|
(46)
|
Net losses on equity investments measured at fair value through
other comprehensive income
|
(28)
|
(171)
|
Fair-value movements related to own credit risk on bonds designated
as fair-value through profit or loss
|
(5)
|
8
|
Tax on items that will not be reclassified to profit or
loss
|
21
|
56
|
|
(376)
|
(153)
|
|
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
40
|
(450)
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
(252)
|
(520)
|
Fair-value movements on cash flow hedges
|
(101)
|
(37)
|
Fair-value movements on cash flow hedges transferred to profit or
loss
|
52
|
111
|
Fair-value movements on derivatives designated in net investment
hedges
|
35
|
(8)
|
Costs of hedging
|
(47)
|
(54)
|
Amortisation of loss on cash flow hedge
|
-
|
1
|
Tax on items that may be reclassified subsequently to profit or
loss
|
38
|
51
|
|
(235)
|
(906)
|
|
|
|
Other comprehensive loss for the period, net of tax
|
(611)
|
(1,059)
|
Total comprehensive income for the period
|
616
|
991
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
1,335
|
2,155
|
Non-controlling interests
|
(108)
|
(105)
|
|
1,227
|
2,050
|
|
|
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
723
|
1,097
|
Non-controlling interests
|
(107)
|
(106)
|
|
616
|
991
|
|
|
|
Basic earnings per $0.25 Ordinary Share
|
$1.03
|
$1.70
|
Diluted earnings per $0.25 Ordinary Share
|
$1.03
|
$1.70
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,301
|
1,267
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,301
|
1,267
|
|
2019
|
2018
|
For the quarter ended 31 December
|
$m
|
$m
|
Product Sales
|
6,250
|
5,768
|
Collaboration Revenue
|
414
|
649
|
|
|
|
Total Revenue
|
6,664
|
6,417
|
Cost of sales
|
(1,378)
|
(1,637)
|
|
|
|
Gross Profit
|
5,286
|
4,780
|
Distribution costs
|
(92)
|
(93)
|
Research and development expense
|
(2,091)
|
(2,012)
|
Selling, general and administrative costs
|
(3,026)
|
(2,600)
|
Other operating income and expense
|
500
|
1,002
|
|
|
|
Operating Profit
|
577
|
1,077
|
Finance income
|
39
|
26
|
Finance expense
|
(351)
|
(337)
|
Share of after-tax losses in associates and joint
ventures
|
(25)
|
(36)
|
|
|
|
Profit Before Tax
|
240
|
730
|
Taxation
|
37
|
279
|
|
|
|
Profit for the period
|
277
|
1,009
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
(213)
|
(184)
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
108
|
(330)
|
Fair-value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
(4)
|
5
|
Tax on items that will not be reclassified to profit or
loss
|
-
|
121
|
|
(109)
|
(388)
|
|
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
425
|
(99)
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
239
|
(71)
|
Fair-value movements on cash flow hedges
|
55
|
(42)
|
Fair-value movements on cash flow hedges transferred to profit or
loss
|
(57)
|
39
|
Fair-value movements on derivatives designated in net investment
hedges
|
-
|
(14)
|
Costs of hedging
|
(12)
|
(19)
|
Amortisation of loss on cash flow hedge
|
-
|
1
|
Tax on items that may be reclassified subsequently to profit or
loss
|
(24)
|
12
|
|
626
|
(193)
|
|
|
|
Other comprehensive income/(loss) for the period, net of
tax
|
517
|
(581)
|
Total comprehensive income for the period
|
794
|
428
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
313
|
1,034
|
Non-controlling interests
|
(36)
|
(25)
|
|
277
|
1,009
|
|
|
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
830
|
453
|
Non-controlling interests
|
(36)
|
(25)
|
|
794
|
428
|
|
|
|
Basic earnings per $0.25 Ordinary Share
|
$0.24
|
$0.82
|
Diluted earnings per $0.25 Ordinary Share
|
$0.24
|
$0.82
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,267
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,267
|
|
At 31 Dec 2019
|
At 31 Dec 2018
|
|
$m
|
$m
|
Assets
|
|
|
Non-current assets
|
|
|
Property, plant and equipment
|
7,688
|
7,421
|
Right-of-use assets
|
647
|
-
|
Goodwill
|
11,668
|
11,707
|
Intangible assets
|
20,833
|
21,959
|
Investments in associates and joint ventures
|
58
|
89
|
Other investments
|
1,401
|
833
|
Derivative financial instruments
|
61
|
157
|
Other receivables
|
740
|
515
|
Deferred tax assets
|
2,718
|
2,379
|
|
45,814
|
45,060
|
Current assets
|
|
|
Inventories
|
3,193
|
2,890
|
Trade and other receivables
|
5,761
|
5,574
|
Other investments
|
849
|
849
|
Derivative financial instruments
|
36
|
258
|
Income tax receivable
|
285
|
207
|
Cash and cash equivalents
|
5,369
|
4,831
|
Assets held for sale
|
70
|
982
|
|
15,563
|
15,591
|
Total assets
|
61,377
|
60,651
|
|
|
|
Liabilities
|
|
|
Current liabilities
|
|
|
Interest-bearing loans and borrowings
|
(1,822)
|
(1,754)
|
Lease liabilities
|
(188)
|
-
|
Trade and other payables
|
(13,987)
|
(12,841)
|
Derivative financial instruments
|
(36)
|
(27)
|
Provisions
|
(723)
|
(506)
|
Income tax payable
|
(1,361)
|
(1,164)
|
|
(18,117)
|
(16,292)
|
Non-current liabilities
|
|
|
Interest-bearing loans and borrowings
|
(15,730)
|
(17,359)
|
Lease liabilities
|
(487)
|
-
|
Derivative financial instruments
|
(18)
|
(4)
|
Deferred tax liabilities
|
(2,490)
|
(3,286)
|
Retirement benefit obligations
|
(2,807)
|
(2,511)
|
Provisions
|
(841)
|
(385)
|
Other payables
|
(6,291)
|
(6,770)
|
|
(28,664)
|
(30,315)
|
Total liabilities
|
(46,781)
|
(46,607)
|
Net assets
|
14,596
|
14,044
|
Equity
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
Share capital
|
328
|
317
|
Share premium account
|
7,941
|
4,427
|
Other reserves
|
2,046
|
2,041
|
Retained earnings
|
2,812
|
5,683
|
|
13,127
|
12,468
|
Non-controlling interests
|
1,469
|
1,576
|
Total equity
|
14,596
|
14,044
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2018
|
317
|
4,393
|
2,029
|
8,221
|
14,960
|
1,682
|
16,642
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards
|
-
|
-
|
-
|
(91)
|
(91)
|
-
|
(91)
|
Profit for the period
|
-
|
-
|
-
|
2,155
|
2,155
|
(105)
|
2,050
|
Other comprehensive loss
|
-
|
-
|
-
|
(1,058)
|
(1,058)
|
(1)
|
(1,059)
|
Transfer to other reserves
|
-
|
-
|
12
|
(12)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,539)
|
(3,539)
|
-
|
(3,539)
|
Issue of Ordinary Shares
|
-
|
34
|
-
|
-
|
34
|
-
|
34
|
Share-based payments charge for the period
|
-
|
-
|
-
|
219
|
219
|
-
|
219
|
Settlement of share plan awards
|
-
|
-
|
-
|
(212)
|
(212)
|
-
|
(212)
|
|
|
|
|
|
|
|
|
Net movement
|
-
|
34
|
12
|
(2,538)
|
(2,492)
|
(106)
|
(2,598)
|
|
|
|
|
|
|
|
|
At 31 Dec 2018
|
317
|
4,427
|
2,041
|
5,683
|
12,468
|
1,576
|
14,044
|
|
|
|
|
|
|
|
|
At 1 Jan 2019
|
317
|
4,427
|
2,041
|
5,683
|
12,468
|
1,576
|
14,044
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards[78]
|
-
|
-
|
-
|
54
|
54
|
-
|
54
|
Profit for the period
|
-
|
-
|
-
|
1,335
|
1,335
|
(108)
|
1,227
|
Other comprehensive loss
|
-
|
-
|
-
|
(612)
|
(612)
|
1
|
(611)
|
Transfer to other reserves
|
-
|
-
|
5
|
(5)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,579)
|
(3,579)
|
-
|
(3,579)
|
Issue of Ordinary Shares[79]
|
11
|
3,514
|
-
|
-
|
3,525
|
-
|
3,525
|
Share-based payments charge for the period
|
-
|
-
|
-
|
259
|
259
|
-
|
259
|
Settlement of share plan awards
|
-
|
-
|
-
|
(323)
|
(323)
|
-
|
(323)
|
|
|
|
|
|
|
|
|
Net movements
|
11
|
3,514
|
5
|
(2,871)
|
659
|
(107)
|
552
|
|
|
|
|
|
|
|
|
At 31 Dec 2019
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
|
2019
|
2018
|
For the year ended 31 December
|
$m
|
$m
|
Cash flows from operating activities
|
|
|
Profit before tax
|
1,548
|
1,993
|
Finance income and expense
|
1,260
|
1,281
|
Share of after-tax losses of associates and joint
ventures
|
116
|
113
|
Depreciation, amortisation and impairment
|
3,762
|
3,753
|
Increase in working capital and short-term provisions
|
(346)
|
(639)
|
Gains on disposal of intangible assets
|
(1,243)
|
(1,885)
|
Fair value movements on contingent consideration arising from
business combinations
|
(614)
|
(495)
|
Non-cash and other movements
|
378
|
(290)
|
|
|
|
Cash generated from operations
|
4,861
|
3,831
|
Interest paid
|
(774)
|
(676)
|
Tax paid
|
(1,118)
|
(537)
|
|
|
|
Net cash inflow from operating activities
|
2,969
|
2,618
|
|
|
|
Cash flows from investing activities
|
|
|
Payment of contingent consideration from business
combinations
|
(709)
|
(349)
|
Purchase of property, plant and equipment
|
(979)
|
(1,043)
|
Disposal of property, plant and equipment
|
37
|
12
|
Purchase of intangible assets
|
(1,481)
|
(328)
|
Disposal of intangible assets
|
2,076
|
2,338
|
Movement in profit-participation liability[80]
|
150
|
-
|
Purchase of non-current asset investments
|
(13)
|
(102)
|
Disposal of non-current asset investments
|
18
|
24
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
194
|
405
|
Payments to associates and joint ventures
|
(74)
|
(187)
|
Interest received
|
124
|
193
|
|
|
|
Net cash (outflow)/inflow from investing activities
|
(657)
|
963
|
|
|
|
Net cash inflow before financing activities
|
2,312
|
3,581
|
|
|
|
Cash flows from financing activities
|
|
|
Proceeds from issue of share capital
|
3,525
|
34
|
Issue of loans
|
500
|
2,971
|
Repayment of loans
|
(1,500)
|
(1,400)
|
Dividends paid
|
(3,592)
|
(3,484)
|
Hedge contracts relating to dividend payments
|
4
|
(67)
|
Repayment of obligations under leases
|
(186)
|
-
|
Movement in short-term borrowings
|
(516)
|
(98)
|
|
|
|
Net cash outflow from financing activities
|
(1,765)
|
(2,044)
|
|
|
|
Net increase in cash and cash equivalents in the
period
|
547
|
1,537
|
Cash and cash equivalents at the beginning of the
period
|
4,671
|
3,172
|
Exchange rate effects
|
5
|
(38)
|
|
|
|
Cash and cash equivalents at the end of the period
|
5,223
|
4,671
|
|
|
|
Cash and cash equivalents consist of:
|
|
|
Cash and cash equivalents
|
5,369
|
4,831
|
Overdrafts
|
(146)
|
(160)
|
|
|
|
|
5,223
|
4,671
|
|
FY 2019
|
FY 2018
|
Q4 201979
|
Q4 201879
|
|
$m
|
$m
|
$m
|
$m
|
Cost of sales
|
73[81]
|
432
|
(49)
|
355
|
Research and development expense
|
101
|
94
|
19
|
(1)
|
Selling, general and administrative costs
|
173
|
181
|
26
|
71
|
Other operating income and expense
|
-
|
(10)
|
-
|
1
|
|
|
|
|
|
Total
|
347
|
697
|
(4)
|
426
|
|
At 1 Jan 2019
|
Adoption of new
accounting standards[82]
|
Cash flow
|
Non-cash & other
|
Exchange movements
|
At 31 Dec 2019
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Non-current instalments of loans
|
(17,359)
|
-
|
-
|
1,578
|
51
|
(15,730)
|
Non-current instalments of leases
|
-
|
(557)
|
-
|
70
|
-
|
(487)
|
|
|
|
|
|
|
|
Total long-term debt
|
(17,359)
|
(557)
|
-
|
1,648
|
51
|
(16,217)
|
|
|
|
|
|
|
|
Current instalments of loans
|
(999)
|
-
|
1,000
|
(1,598)
|
-
|
(1,597)
|
Current instalments of leases
|
-
|
(163)
|
206
|
(231)
|
-
|
(188)
|
Commercial paper
|
(211)
|
-
|
211
|
-
|
-
|
-
|
Bank collateral
|
(384)
|
-
|
313
|
-
|
-
|
(71)
|
Other short-term borrowings excluding overdrafts
|
-
|
-
|
(8)
|
-
|
-
|
(8)
|
Overdraft
|
(160)
|
-
|
13
|
-
|
1
|
(146)
|
|
|
|
|
|
|
|
Total current debt
|
(1,754)
|
(163)
|
1,735
|
(1,829)
|
1
|
(2,010)
|
|
|
|
|
|
|
|
Gross borrowings
|
(19,113)
|
(720)
|
1,735
|
(181)
|
52
|
(18,227)
|
|
|
|
|
|
|
|
Net derivative financial instruments
|
384
|
-
|
(214)
|
(127)
|
-
|
43
|
|
|
|
|
|
|
|
Net borrowings
|
(18,729)
|
(720)
|
1,521
|
(308)
|
52
|
(18,184)
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
4,831
|
-
|
534
|
-
|
4
|
5,369
|
Other investments - current
|
849
|
-
|
16
|
(14)
|
(2)
|
849
|
Other investments - non-current
|
46
|
-
|
-
|
16
|
-
|
62
|
Cash and investments
|
5,726
|
-
|
550
|
2
|
2
|
6,280
|
|
|
|
|
|
|
|
Net debt
|
(13,003)
|
(720)
|
2,071
|
(306)
|
54
|
(11,904)
|
|
Diabetes alliance
2019
|
Other
2019
|
Total
2019
|
Total
2018
|
|
$m
|
$m
|
$m
|
$m
|
At 1 January
|
3,983
|
1,123
|
5,106
|
5,534
|
Settlements
|
(454)
|
(255)
|
(709)
|
(349)
|
Revaluations
|
(516)
|
(98)
|
(614)
|
(495)
|
Discount unwind
|
287
|
69
|
356
|
416
|
|
|
|
|
|
At 31 December
|
3,300
|
839
|
4,139
|
5,106
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
FY 2019
|
Actual
|
CER
|
FY 2019
|
Actual
|
CER
|
FY 2019
|
Actual
|
FY 2019
|
Actual
|
CER
|
FY 2019
|
Actual
|
CER
|
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
3,189
|
71
|
74
|
762
|
n/m
|
n/m
|
1,268
|
46
|
474
|
51
|
59
|
685
|
n/m
|
n/m
|
Imfinzi
|
1,469
|
n/m
|
n/m
|
30
|
n/m
|
n/m
|
1,041
|
85
|
179
|
n/m
|
n/m
|
219
|
n/m
|
n/m
|
Lynparza
|
1,198
|
85
|
89
|
133
|
n/m
|
n/m
|
626
|
81
|
287
|
51
|
59
|
152
|
n/m
|
n/m
|
Calquence
|
164
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
162
|
n/m
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
Faslodex
|
892
|
(13)
|
(11)
|
198
|
29
|
36
|
328
|
(39)
|
229
|
3
|
9
|
137
|
19
|
17
|
Zoladex*
|
813
|
8
|
13
|
492
|
20
|
28
|
7
|
(17)
|
135
|
2
|
7
|
179
|
(11)
|
(10)
|
Iressa*
|
423
|
(18)
|
(15)
|
286
|
-
|
4
|
17
|
(33)
|
70
|
(36)
|
(32)
|
50
|
(49)
|
(49)
|
Arimidex*
|
225
|
6
|
11
|
152
|
15
|
21
|
-
|
n/m
|
28
|
(8)
|
(3)
|
45
|
(9)
|
(9)
|
Casodex*
|
200
|
-
|
3
|
127
|
13
|
19
|
-
|
(88)
|
16
|
(20)
|
(15)
|
57
|
(15)
|
(15)
|
Others
|
94
|
(18)
|
(17)
|
29
|
(6)
|
(3)
|
-
|
n/m
|
5
|
(24)
|
(19)
|
60
|
(21)
|
(22)
|
Total Oncology
|
8,667
|
44
|
47
|
2,211
|
45
|
52
|
3,449
|
43
|
1,423
|
35
|
42
|
1,584
|
53
|
52
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
1,543
|
11
|
14
|
471
|
40
|
48
|
537
|
(9)
|
373
|
18
|
25
|
162
|
9
|
10
|
Brilinta
|
1,581
|
20
|
23
|
462
|
42
|
49
|
710
|
21
|
351
|
1
|
7
|
58
|
(1)
|
3
|
Bydureon
|
549
|
(6)
|
(5)
|
11
|
34
|
39
|
459
|
(3)
|
66
|
(19)
|
(14)
|
13
|
(32)
|
(28)
|
Onglyza
|
527
|
(3)
|
-
|
176
|
3
|
9
|
230
|
3
|
70
|
(22)
|
(17)
|
51
|
(14)
|
(12)
|
Byetta
|
110
|
(13)
|
(11)
|
12
|
47
|
60
|
68
|
(9)
|
19
|
(35)
|
(31)
|
11
|
(24)
|
(20)
|
Other diabetes
|
52
|
33
|
35
|
1
|
n/m
|
n/m
|
40
|
18
|
9
|
88
|
n/m
|
2
|
23
|
33
|
Lokelma
|
14
|
n/m
|
n/m
|
-
|
-
|
-
|
13
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Crestor*
|
1,278
|
(11)
|
(8)
|
806
|
(4)
|
-
|
104
|
(39)
|
148
|
(27)
|
(23)
|
220
|
-
|
1
|
Seloken/Toprol-XL*
|
760
|
7
|
12
|
686
|
7
|
13
|
37
|
(5)
|
25
|
31
|
31
|
12
|
(11)
|
(8)
|
Atacand*
|
221
|
(15)
|
(11)
|
160
|
2
|
7
|
12
|
(11)
|
30
|
(57)
|
(57)
|
19
|
1
|
7
|
Others
|
271
|
(9)
|
(6)
|
193
|
(6)
|
(3)
|
(1)
|
(91)
|
59
|
(16)
|
(12)
|
20
|
(16)
|
(16)
|
BioPharmaceuticals: total CVRM
|
6,906
|
3
|
6
|
2,978
|
10
|
16
|
2,209
|
n/m
|
1,151
|
(6)
|
(1)
|
568
|
(2)
|
n/m
|
BioPharmaceuticals: Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
2,495
|
(3)
|
-
|
547
|
11
|
17
|
829
|
(4)
|
678
|
(12)
|
(7)
|
441
|
2
|
3
|
Pulmicort
|
1,466
|
14
|
18
|
1,190
|
20
|
24
|
110
|
(5)
|
81
|
(10)
|
(4)
|
85
|
1
|
1
|
Fasenra
|
704
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
482
|
n/m
|
118
|
n/m
|
n/m
|
99
|
n/m
|
n/m
|
Daliresp/Daxas
|
215
|
14
|
15
|
4
|
(18)
|
(13)
|
184
|
19
|
26
|
(8)
|
(3)
|
1
|
32
|
35
|
Duaklir
|
77
|
(19)
|
(15)
|
1
|
44
|
49
|
3
|
-
|
71
|
(22)
|
(17)
|
2
|
(65)
|
(64)
|
Bevespi
|
42
|
26
|
26
|
-
|
n/m
|
n/m
|
42
|
25
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
Breztri
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
Others
|
390
|
(13)
|
(9)
|
240
|
62
|
70
|
3
|
(88)
|
133
|
(38)
|
(35)
|
14
|
(74)
|
(73)
|
BioPharmaceuticals: total Respiratory
|
5,391
|
10
|
13
|
1,987
|
21
|
27
|
1,653
|
17
|
1,107
|
(10)
|
(5)
|
644
|
4
|
4
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
1,483
|
(13)
|
(11)
|
748
|
8
|
14
|
218
|
(29)
|
63
|
(73)
|
(72)
|
454
|
(4)
|
(4)
|
Synagis
|
358
|
(46)
|
(46)
|
-
|
(100)
|
(100)
|
46
|
(84)
|
312
|
(17)
|
(17)
|
-
|
n/m
|
n/m
|
Losec/Prilosec
|
263
|
(3)
|
1
|
179
|
11
|
17
|
10
|
43
|
49
|
(30)
|
(26)
|
25
|
(27)
|
(26)
|
Seroquel XR/IR
|
191
|
(47)
|
(46)
|
50
|
(58)
|
(57)
|
34
|
(69)
|
88
|
(18)
|
(14)
|
19
|
(30)
|
(30)
|
Others
|
306
|
(23)
|
(20)
|
12
|
(77)
|
(81)
|
128
|
(4)
|
157
|
(1)
|
2
|
9
|
(84)
|
(67)
|
Total other medicines
|
2,601
|
(24)
|
(21)
|
989
|
(3)
|
1
|
436
|
(48)
|
669
|
(29)
|
(28)
|
507
|
(14)
|
(12)
|
Total Product Sales
|
23,565
|
12
|
15
|
8,165
|
18
|
24
|
7,747
|
13
|
4,350
|
(2)
|
2
|
3,303
|
17
|
18
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
Q4 2019
|
Actual
|
CER
|
Q4 2019
|
Actual
|
CER
|
Q4 2019
|
Actual
|
Q4 2019
|
Actual
|
CER
|
Q4 2019
|
Actual
|
CER
|
|
$m
|
%
|
%
|
$m
|
%
|
%
|
$m
|
%
|
$m
|
%
|
%
|
$m
|
%
|
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
884
|
49
|
49
|
209
|
n/m
|
n/m
|
359
|
24
|
137
|
48
|
54
|
179
|
36
|
32
|
Imfinzi
|
424
|
62
|
62
|
12
|
n/m
|
n/m
|
282
|
31
|
64
|
n/m
|
n/m
|
66
|
n/m
|
n/m
|
Lynparza
|
351
|
68
|
69
|
32
|
81
|
86
|
194
|
73
|
79
|
48
|
54
|
46
|
75
|
69
|
Calquence
|
56
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
54
|
n/m
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
Faslodex
|
166
|
(39)
|
(38)
|
53
|
24
|
25
|
17
|
(88)
|
61
|
20
|
25
|
35
|
8
|
4
|
Zoladex*
|
196
|
8
|
9
|
112
|
17
|
20
|
2
|
(20)
|
35
|
4
|
8
|
46
|
(6)
|
(8)
|
Iressa*
|
80
|
(29)
|
(28)
|
59
|
(1)
|
-
|
3
|
(40)
|
9
|
(63)
|
(62)
|
8
|
(64)
|
(65)
|
Arimidex*
|
51
|
10
|
11
|
34
|
28
|
31
|
-
|
n/m
|
7
|
(12)
|
(9)
|
11
|
(15)
|
(18)
|
Casodex*
|
43
|
(6)
|
(5)
|
28
|
22
|
25
|
-
|
n/m
|
4
|
(23)
|
(20)
|
11
|
(38)
|
(40)
|
Others
|
26
|
15
|
12
|
7
|
4
|
4
|
-
|
n/m
|
-
|
(56)
|
(54)
|
18
|
34
|
29
|
Total Oncology
|
2,274
|
29
|
29
|
546
|
54
|
57
|
911
|
15
|
396
|
38
|
43
|
421
|
27
|
22
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
419
|
6
|
7
|
132
|
40
|
42
|
141
|
(18)
|
100
|
18
|
23
|
47
|
(2)
|
(3)
|
Brilinta
|
428
|
14
|
15
|
114
|
21
|
23
|
210
|
18
|
89
|
(3)
|
1
|
15
|
7
|
11
|
Bydureon
|
139
|
1
|
1
|
2
|
n/m
|
n/m
|
119
|
3
|
16
|
(19)
|
(15)
|
2
|
(40)
|
(38)
|
Onglyza
|
131
|
(11)
|
(10)
|
45
|
(11)
|
(8)
|
56
|
(8)
|
17
|
(22)
|
(19)
|
13
|
(13)
|
(12)
|
Byetta
|
27
|
(16)
|
(15)
|
4
|
90
|
92
|
16
|
(15)
|
5
|
(38)
|
(35)
|
2
|
(32)
|
(30)
|
Other diabetes
|
16
|
35
|
36
|
-
|
n/m
|
n/m
|
12
|
13
|
2
|
42
|
49
|
1
|
(63)
|
(61)
|
Lokelma
|
8
|
n/m
|
n/m
|
-
|
-
|
-
|
7
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Crestor*
|
296
|
(16)
|
(15)
|
185
|
(12)
|
(10)
|
16
|
(63)
|
36
|
(16)
|
(13)
|
58
|
2
|
(1)
|
Seloken/Toprol-XL*
|
190
|
18
|
20
|
173
|
17
|
19
|
7
|
13
|
7
|
n/m
|
n/m
|
4
|
2
|
4
|
Atacand*
|
60
|
3
|
5
|
43
|
(1)
|
-
|
4
|
85
|
8
|
(1)
|
(1)
|
5
|
15
|
19
|
Others
|
72
|
1
|
4
|
54
|
6
|
8
|
(1)
|
-
|
13
|
(14)
|
(11)
|
5
|
7
|
5
|
BioPharmaceuticals: total CVRM
|
1,785
|
2
|
4
|
753
|
9
|
11
|
587
|
(3)
|
293
|
(1)
|
3
|
152
|
(2)
|
(3)
|
BioPharmaceuticals: Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
712
|
12
|
13
|
146
|
12
|
14
|
244
|
18
|
170
|
(8)
|
(5)
|
152
|
34
|
32
|
Pulmicort
|
413
|
6
|
7
|
345
|
12
|
14
|
21
|
(40)
|
21
|
(2)
|
2
|
25
|
3
|
-
|
Fasenra
|
206
|
65
|
65
|
1
|
82
|
88
|
139
|
56
|
37
|
n/m
|
n/m
|
29
|
45
|
41
|
Daliresp/Daxas
|
58
|
8
|
8
|
1
|
1
|
3
|
50
|
12
|
7
|
(19)
|
(16)
|
-
|
n/m
|
n/m
|
Duaklir
|
22
|
(2)
|
-
|
-
|
n/m
|
n/m
|
3
|
-
|
18
|
(12)
|
(11)
|
1
|
(119)
|
(120)
|
Bevespi
|
12
|
12
|
12
|
-
|
n/m
|
n/m
|
12
|
11
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
Breztri
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
Others
|
114
|
(9)
|
(7)
|
75
|
29
|
32
|
-
|
n/m
|
35
|
(37)
|
(36)
|
4
|
(69)
|
(68)
|
BioPharmaceuticals: total Respiratory
|
1,537
|
13
|
14
|
568
|
14
|
16
|
470
|
22
|
288
|
(6)
|
(3)
|
211
|
22
|
20
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
353
|
(10)
|
(10)
|
174
|
5
|
6
|
43
|
(25)
|
14
|
(74)
|
(73)
|
122
|
10
|
6
|
Synagis
|
63
|
(75)
|
(75)
|
-
|
(100)
|
(100)
|
10
|
(94)
|
54
|
(44)
|
(44)
|
-
|
n/m
|
n/m
|
Losec/Prilosec
|
46
|
(24)
|
(23)
|
34
|
12
|
14
|
3
|
55
|
4
|
(78)
|
(78)
|
5
|
(49)
|
(51)
|
Seroquel XR/IR
|
40
|
(27)
|
(27)
|
9
|
(27)
|
(27)
|
7
|
(49)
|
21
|
(20)
|
(17)
|
4
|
(13)
|
(15)
|
Others
|
151
|
12
|
14
|
8
|
(42)
|
(47)
|
29
|
1
|
111
|
27
|
30
|
4
|
(31)
|
(30)
|
Total other medicines
|
653
|
(27)
|
(27)
|
224
|
n/m
|
2
|
91
|
(64)
|
204
|
(28)
|
(27)
|
134
|
3
|
n/m
|
Total Product Sales
|
6,250
|
8
|
9
|
2,091
|
18
|
20
|
2,059
|
1
|
1,182
|
1
|
4
|
918
|
16
|
13
|
|
Q1 2019
|
Actual
|
CER
|
Q2 2019
|
Actual
|
CER
|
Q3 2019
|
Actual
|
CER
|
Q4 2019
|
Actual
|
CER
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
630
|
6
|
6
|
784
|
24
|
25
|
891
|
14
|
13
|
884
|
(1)
|
-
|
Imfinzi
|
295
|
13
|
13
|
338
|
15
|
15
|
412
|
22
|
22
|
424
|
3
|
4
|
Lynparza
|
237
|
13
|
13
|
283
|
19
|
20
|
327
|
16
|
15
|
351
|
7
|
8
|
Calquence
|
29
|
21
|
23
|
35
|
21
|
19
|
44
|
27
|
27
|
56
|
25
|
25
|
Faslodex
|
254
|
(6)
|
(6)
|
267
|
5
|
6
|
205
|
(23)
|
(23)
|
166
|
(20)
|
(19)
|
Zoladex*
|
194
|
7
|
6
|
197
|
2
|
1
|
226
|
15
|
16
|
196
|
(14)
|
(12)
|
Iressa*
|
134
|
20
|
18
|
118
|
(12)
|
(11)
|
91
|
(23)
|
(22)
|
80
|
(13)
|
(12)
|
Arimidex*
|
51
|
11
|
10
|
60
|
18
|
17
|
63
|
5
|
5
|
51
|
(20)
|
(18)
|
Casodex*
|
48
|
4
|
3
|
57
|
19
|
18
|
52
|
(8)
|
(6)
|
43
|
(18)
|
(17)
|
Others
|
20
|
(13)
|
(14)
|
28
|
40
|
29
|
20
|
(27)
|
(22)
|
26
|
30
|
26
|
Total Oncology
|
1,892
|
7
|
6
|
2,167
|
15
|
15
|
2,334
|
8
|
8
|
2,274
|
(3)
|
(2)
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
349
|
(12)
|
(12)
|
377
|
8
|
9
|
398
|
5
|
5
|
419
|
5
|
6
|
Brilinta
|
348
|
(7)
|
(8)
|
389
|
12
|
12
|
416
|
7
|
8
|
428
|
3
|
3
|
Bydureon
|
142
|
3
|
3
|
141
|
(1)
|
-
|
127
|
(10)
|
(10)
|
139
|
9
|
10
|
Onglyza
|
153
|
3
|
3
|
116
|
(24)
|
(24)
|
127
|
9
|
11
|
131
|
3
|
4
|
Byetta
|
30
|
(6)
|
(5)
|
25
|
(17)
|
(16)
|
28
|
10
|
13
|
27
|
(2)
|
(4)
|
Other diabetes
|
11
|
(8)
|
(17)
|
11
|
-
|
8
|
14
|
26
|
22
|
16
|
17
|
17
|
Lokelma
|
-
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
4
|
m/n
|
n/m
|
8
|
87
|
74
|
Crestor*
|
335
|
(5)
|
(6)
|
310
|
(7)
|
(7)
|
337
|
9
|
9
|
296
|
(12)
|
(11)
|
Seloken/Toprol-XL*
|
225
|
41
|
38
|
168
|
(25)
|
(25)
|
177
|
6
|
8
|
190
|
7
|
8
|
Atacand*
|
50
|
(14)
|
(15)
|
56
|
12
|
14
|
55
|
(1)
|
(1)
|
60
|
8
|
9
|
Others
|
71
|
(3)
|
(5)
|
63
|
(11)
|
(8)
|
65
|
4
|
2
|
72
|
13
|
16
|
BioPharmaceuticals: total CVRM
|
1,714
|
(2)
|
(3)
|
1,658
|
(3)
|
(3)
|
1,749
|
5
|
6
|
1,785
|
2
|
3
|
BioPharmaceuticals: Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
585
|
(8)
|
(8)
|
585
|
-
|
1
|
613
|
5
|
4
|
712
|
16
|
17
|
Pulmicort
|
383
|
(2)
|
(2)
|
333
|
(13)
|
(13)
|
337
|
1
|
3
|
413
|
22
|
23
|
Fasenra
|
129
|
3
|
4
|
167
|
29
|
30
|
202
|
21
|
21
|
206
|
2
|
2
|
Daliresp/Daxas
|
48
|
(11)
|
(12)
|
56
|
17
|
18
|
53
|
(6)
|
(7)
|
58
|
10
|
10
|
Duaklir
|
20
|
(9)
|
(6)
|
17
|
(15)
|
(16)
|
18
|
7
|
5
|
22
|
19
|
20
|
Bevespi
|
10
|
-
|
(5)
|
10
|
-
|
2
|
10
|
4
|
8
|
12
|
8
|
5
|
Breztri
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
1
|
(74)
|
(73)
|
Others
|
108
|
(14)
|
(16)
|
84
|
(22)
|
(23)
|
84
|
-
|
4
|
114
|
36
|
35
|
BioPharmaceuticals: total Respiratory
|
1,283
|
(6)
|
(6)
|
1,252
|
(2)
|
(2)
|
1,319
|
5
|
6
|
1,537
|
17
|
17
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
363
|
(7)
|
(8)
|
393
|
8
|
8
|
374
|
(5)
|
(4)
|
353
|
(6)
|
(6)
|
Synagis
|
53
|
(79)
|
(79)
|
96
|
81
|
81
|
146
|
52
|
53
|
63
|
(57)
|
(57)
|
Losec/Prilosec
|
76
|
27
|
26
|
68
|
(11)
|
(10)
|
73
|
8
|
9
|
46
|
(38)
|
(38)
|
Seroquel XR/IR
|
37
|
(34)
|
(33)
|
32
|
(14)
|
(10)
|
82
|
n/m
|
n/m
|
40
|
(50)
|
(49)
|
Others
|
47
|
(65)
|
(64)
|
52
|
11
|
11
|
56
|
8
|
-
|
151
|
n/m
|
n/m
|
Total other medicines
|
576
|
(35)
|
(36)
|
641
|
11
|
12
|
731
|
14
|
14
|
653
|
(11)
|
(10)
|
Total Product Sales
|
5,465
|
(5)
|
(6)
|
5,718
|
5
|
5
|
6,132
|
7
|
8
|
6,250
|
2
|
3
|
Shareholder information
|
|
|
Announcement
first quarter 2019 results and Annual General Meeting:
|
29
April 2020
|
|
Announcement
of first half and second quarter results
|
30 July
2020
|
|
Announcement
of year to date and third quarter results
|
5
November 2020
|
|
|
|
|
Future
dividends will normally be paid as follows:
|
|
|
First
interim:
|
announced
with half-year and second-quarter results and paid in
September
|
|
Second
interim:
|
announced
with full-year and fourth-quarter results and paid in
March
|
|
|
|
|
Addresses for correspondence
|
||||
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
|
|
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|